Qinjin Fan, PhD, on Equitable Lung Cancer Care and Mortgage Discrimination

2022 ASCO Quality Care Symposium


Qinjin Fan, PhD, of the American Cancer Society, explores the question of how mortgage discrimination is linked to lower rates of guideline-concordant care for patients with non–small cell lung cancer. This study highlights the critical need to understand the pathways through which mortgage denials may negatively affect the receipt of equitable care (Abstract 3).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
As we know that lung cancer is the second most common cancer diagnosed and the leading cause of cancer death in the United States. And the housing insecurity is a important social determinant of health that can influence and be influenced by cancer diagnosis and care across the continuum. So, there are multiple pathways through which housing insecurity can affect cancer patients, and one of them is housing discrimination. In this study, we look at the area level mortgage denial rate as a marker for the sustained lending discrimination and the neighborhood disinvestment. And we then investigated the association between residing in areas with high mortgage denial rates and the result of quality cancer care and outcome among individuals diagnosed with non-small cell lung cancer. To investigate that, we selected individuals diagnosed with non-small cell lung cancer between 2014 to 2019, from the National Cancer database. So, the NCDP is a nationwide hospital-based cancer registry. It captures about 70% newly diagnosed cases in the US and it is co-sponsored by the American College of Surgeons at American Cancer Society, and it collects detailed and standardized information on patients tumor treatment and outcomes in all states. The mortgage data were collected from the Home Mortgage Disclosure Act database, which is publicly available and has information on mortgage lending practices. So, we estimated the mortgage denial rate as the proportion of denied home loans, to the total of completed home loans. And we categorize them into quantiles, where level one is the lowest, and the level four is the highest. And in this study, we have multiple outcomes of interest. First, the result of guideline concordant care, including surgery or radiation, lymph nodes evaluation, new adjuvant chemo radiation and adjuvant chemotherapy. So, the treatment eligibility and the result of guideline concordant care were defined based on the National Comprehensive Cancer Network guidelines. Our results showed that individuals residing in areas with high mortgage denial rates were less likely to receive guideline concordant care for non-small cell lung cancer. And this association was consistent across all treatment sub-groups, with an exception for new adjuvant chemo radiation. Similarly, we found that individual residing in areas with high mortgage denial rates had worse access to timely chemotherapy and had worse overall survival. Our findings highlight the critical needs to understand the pathways, through which institutional practices leading to barriers in access to resources such as mortgage denials, can negatively affect access to equitable cancer care and outcomes.

Related Videos


Christopher E. Jensen, MD, on Older Adults With AML: A Price Paid for High-Intensity Chemotherapy?

Christopher E. Jensen, MD, of the University of North Carolina School of Medicine, talks about older adults with acute myeloid leukemia who receive high-intensity chemotherapy. Although they may live longer, much of their survival gains may be spent engaged in oncology care (Abstract 376).

Colorectal Cancer

S.M. Qasim Hussaini, MD, on Colon Cancer Treatment Outcomes and Historical Housing Discrimination

S. M. Qasim Hussaini, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, discusses findings from a nationwide study of the association between living in areas with discriminatory mortgage practices from the 1930s with present-day access to quality colon cancer care. The study underscores the importance of state- and federal-level practices on mortgage lending regulation and fair housing practices in determining equitable cancer risk, access to care, and outcomes (Abstract 69).

Issues in Oncology

Joannie M. Ivory, MD, MSPH, on Increasing Participation of Black Patients With Cancer in Clinical Trials

Joannie M. Ivory, MD, MSPH, of The University of North Carolina at Chapel Hill, discusses ways to raise the number of Black patients with cancer who take part in clinical trials. More successful accrual may be linked to conducting trials where Black patients live and designing studies to recruit a concrete target percentage of marginalized populations.

Symptom Management
Supportive Care

Sandra L. Wong, MD, on Severe Symptom Reporting in Patients With Cancer Who Have Undergone Surgery

Sandra L. Wong, MD, of the Dartmouth-Hitchcock Medical Center, discusses her study findings showing that when patients with cancer who have had surgery reported severe symptoms via an electronic patient-reported outcomes questionnaire at six cancer centers, it appeared to be beneficial without overtaxing clinicians. There were few strong predictors of severe symptoms, which suggests population surveillance may be preferable to targeted surveillance (Abstract 243).

Breast Cancer
Issues in Oncology

Regina Barragán-Carrillo, MD, on Breast Cancer Screening in the Transgender Population

Regina Barragán-Carrillo, MD, of Mexico’s National Institute of Medical Sciences and Nutrition Salvador Zubirán, discusses her findings showing that currently, physicians have limited knowledge about breast cancer screening in transgender patients. Were this topic addressed with widespread information, it could possibly reduce the health-care inequalities faced by this diverse group of patients (Abstract 71).